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Abstract
The neuronal calcium sensor proteins GCAPs (guanylate cyclase activating proteins) switch between Ca2+-free and Ca2+-
bound conformational states and confer calcium sensitivity to guanylate cyclase at retinal photoreceptor cells. They play a
fundamental role in light adaptation by coupling the rate of cGMP synthesis to the intracellular concentration of calcium.
Mutations in GCAPs lead to blindness. The importance of functional EF-hands in GCAP1 for photoreceptor cell integrity has
been well established. Mutations in GCAP1 that diminish its Ca2+ binding affinity lead to cell damage by causing unabated
cGMP synthesis and accumulation of toxic levels of free cGMP and Ca2+. We here investigate the relevance of GCAP2
functional EF-hands for photoreceptor cell integrity. By characterizing transgenic mice expressing a mutant form of GCAP2
with all EF-hands inactivated (EF2GCAP2), we show that GCAP2 locked in its Ca2+-free conformation leads to a rapid retinal
degeneration that is not due to unabated cGMP synthesis. We unveil that when locked in its Ca2+-free conformation in vivo,
GCAP2 is phosphorylated at Ser201 and results in phospho-dependent binding to the chaperone 14-3-3 and retention at
the inner segment and proximal cell compartments. Accumulation of phosphorylated EF2GCAP2 at the inner segment
results in severe toxicity. We show that in wildtype mice under physiological conditions, 50% of GCAP2 is phosphorylated
correlating with the 50% of the protein being retained at the inner segment. Raising mice under constant light exposure,
however, drastically increases the retention of GCAP2 in its Ca2+-free form at the inner segment. This study identifies a new
mechanism governing GCAP2 subcellular distribution in vivo, closely related to disease. It also identifies a pathway by which
a sustained reduction in intracellular free Ca2+ could result in photoreceptor damage, relevant for light damage and for
those genetic disorders resulting in ‘‘equivalent-light’’ scenarios.
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Introduction
Guanylate-cyclase activating proteins (GCAPs) belong to the
neuronal calcium sensor (NCS) family of proteins that display
limited similarity to calmodulin. They confer Ca2+-sensitivity to
guanylate-cyclase (Ret-GC) activity in retinal photoreceptor cells.
GCAP1 and GCAP2 constitute the major species in mammals [1–
3]. At rod and cone outer segments GCAPs form permanent
complexes with Ret-GCs allowing short response times of cyclase
modulation to fluctuations in intracellular Ca2+ concentration.
GCAPs inhibit cyclase activity in their Ca2+-loaded form at the
high free [Ca2+]i characteristic of the dark steady-state, and switch
to their activator state as they replace Ca2+ by Mg2+ when light
reduces Ca2+ influx upon closing the cGMP-channels [4]. Light
exposure results in up to a 10-fold decline in the intracellular free
[Ca2+], from ,250 nM in darkness to 23 nM in saturating light in
mouse rod outer segments [5]. This Ca2+ decrease is first sensed at
GC/GCAP complexes comprising GCAP1 and successively at
those comprising GCAP2 [Ca2+ EC50 for GCAP1 ,130 nM; for
GCAP2 ,50 nM, [6]], in a sequential mode of action referred to
as a Ca2+-relay model [7–9]. Altogether, the rate of cGMP
synthesis upon light exposure is stimulated up to ,12-fold over its
basal levels, serving to restore the cGMP levels and to reopen the
channels during the recovery of the light response and light
adaptation [10,11].
Despite the importance of GCAPs-mediated Ca2+-feedback on
cGMP synthesis in the control of sensitivity, deletion of GCAP1
and GCAP2 in mice does not lead to significant effects on retinal
morphology, indicating that GCAPs are not essential for the
development or maintenance of retinal organization [11].
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However, mutations in the GCAP1 and GCAP2 genes have been
linked to inherited autosomal dominant retinopathies. Ten
heterozygous mutations in the GUCA1A gene encoding GCAP1
have been linked to autosomal dominant cone dystrophy (adCD),
cone rod dystrophy (adCRD) or macular degeneration (adMD)
[12–20]. One mutation in the GUCA1B gene, G157R, has been
associated to autosomal dominant retinal dystrophies ranging from
retinitis pigmentosa to macular degeneration [21].
Most of GCAP1 mutations map at EF-hand domains and affect
Ca2+ coordination directly, such as D100E and N104K at EF-3 or
L151F and E155G at EF-4 [13–15,20], or map at the incoming or
outgoing a-helixes in EF-3 and EF-4, such as E89K, Y99C,
T114I, I143NT and G159V, causing conformational distortions
that make Ca2+ binding less favorable [15,17,18]. These mutations
shift the Ca2+ IC50 of GC activation to higher free [Ca
2+], so that
in vitro the mutant proteins fail to switch to the inhibitory state
and lead to persistent activation of RetGC in the whole
physiological range of [Ca2+]i [15,20,22–24]. In vivo, as demon-
strated for the Y99C and E155G GCAP1 mutations, the unabated
cGMP synthesis results in abnormally high levels of cGMP and
Ca2+ in rods, and the ensuing retinal degeneration can be
significantly prevented by conditions that promote constitutive
stimulation of PDE6 such as constant light exposure [23,25,26].
There are aspects of GCAPs that remain less understood, such
as their Ca2+-dependent structural changes or the mechanisms
that determine their cellular distribution. GCAP1 and GCAP2 are
both myristoylated at the NH2-terminus. While myristoylation of
GCAP1 not only affects the affinity of GCAP1 for Ret-GC and
Ret-GC maximal activation, but also increases the Ca2+ sensitivity
of Ret-GC inhibition at EF-4 [27], myristoylation of GCAP2
affects its overall structural stability without affecting Ret-GC
regulation [28]. Both GCAP1 and GCAP2 form homodimers
upon Ca2+ dissociation, with the capacity to dimerize in GCAP2
correlating with the ability to activate Ret-GC [29]. However,
while in GCAP2 dimerization is reversed by Ca2+ binding,
GCAP1 dimerization is resistant to the presence of Ca2+, implying
a difference in their Ca2+-dependent conformational changes [29].
Overall, the Ca2+-free form of GCAP2 shows a higher tendency to
aggregate than GCAP1. In addition, Ca2+-dependent conforma-
tional changes in GCAP2 have been shown to correlate with a site-
specific phosphorylation at Ser201, the significance of which is not
yet clear as it does not affect Ret-GC regulation in vitro [30].
Regarding their cellular localization, GCAP1 is more abundant
at cone than at rod outer segments [31]. GCAP2 localizes
primarily to rods and at lower levels in cones. In rods, GCAP2
localization is not restricted to rod outer segments. It is present at
rod inner segments at about the same level, and at lower levels in
more proximal compartments of the cell [32,33]. At the synaptic
terminal GCAP2 has been shown to interact with Ribeye, the
major structural component of synaptic ribbons, and to lead to
significant alterations of synaptic ribbon dynamics when overex-
pressed in vivo [34,35]. The mechanisms that determine GCAPs
subcellular distribution are largely unknown, but it was proposed
that GCAPs are transported by vesicular trafficking guided by Ret-
GCs, in a process assisted by RD3 [36,37].
To study whether genetic mutations or light conditions that
would preclude Ca2+-binding to GCAP2 would compromise rod
cell viability by an analogous mechanism by which GCAP1 EF-
hand mutations do, we set to study the effect of expressing in rods
a mutant form of GCAP2 impaired to bind Ca2+: GCAP2 with all
functional EF hands inactivated (bEF2GCAP2) [38]. Whereas in
vitro bEF2GCAP2 shows a similar biochemical behavior as
Y99C-GCAP1 [24,38], we show that in vivo it leads to a rapid
retinal degeneration by a mechanism independent of cGMP
metabolism. In vivo, the protein accumulates at the inner segment,
in a form that is largely incompetent to activate the cyclase. It
binds to 14-3-3 protein isoforms due to enhanced phosphorylation
at Ser201. We show that the cause of the pathology in
bEF2GCAP2 mice is not constitutive activation of the cyclase,
but rather the accumulation of the phosphorylated protein at the
proximal compartments of the cell, likely in a conformationally
unstable form stabilized by 14-3-3 binding, that ultimately causes
extensive damage to the cell. We propose that this mechanism will
contribute to the pathology of those inherited retinal dystrophies
caused by mutations in different genes that share as an initial
consequence of the mutation the sustained reduction of the
intracellular concentration of Ca2+, the so-called ‘‘light-equivalent
damage’’ scenarios.
Results
Transgenic expression of bEF2GCAP2 in mouse rods
leads to progressive retinal degeneration
To study the relevance of functional EF-hand domains in
GCAP2 for protein activity and photoreceptor cell integrity in
vivo, we expressed a mutant form of GCAP2 with inactivated EF
hands: GCAP2(E80Q/E116Q/D158N), hereafter referred to as
bEF2GCAP2, in the rod photoreceptors of transgenic mice
(Fig. 1A). It was previously shown that inactivation of the three
functional EF hands in bGCAP2 abolishes its capacity to bind
Ca2+ [38]. To generate transgenic mice we expressed the cDNA of
the bovine GCAP2 isoform, so that the transgene product could be
distinguished from the endogenous murine form by SDS-PAGE
electrophoretic mobility. To discriminate the effect of the
mutations in GCAP2 from the effect that overexpression of
GCAP2 might have on the cell, we included in the study a control
transgenic line that expresses wildtype bovine GCAP2 (line E,
Fig. 1A,B). This line was reported to express wildtype bovine
GCAP2 at a ,2:1 ratio relative to endogenous GCAP2 [11].
We established two independent transgenic lines that expressed
different levels of bEF2GCAP2. Line A expressed bEF2GCAP2 at
a ratio of 2.76:1 relative to endogenous GCAP2, whereas line B
Author Summary
Visual perception is initiated at retinal photoreceptor cells,
where light activates an enzymatic cascade that reduces
free cGMP. As cGMP drops, cGMP-channels close and
reduce the inward current –including Ca2+ influx– so that
photoreceptors hyperpolarize and emit a signal. As the
light extinguishes, cGMP levels are restored to reestablish
sensitivity. cGMP synthesis relies on guanylate cyclase/
guanylate cyclase activating protein (RetGC/GCAP) com-
plexes. GCAPs link the rate of cGMP synthesis to
intracellular Ca2+ levels, by switching between a Ca2+-free
state that activates cGMP synthesis during light exposure,
and a Ca2+-bound state that arrests cGMP synthesis in the
dark. It is established that GCAP1 mutations linked to
adCORD disrupt this tight Ca2+ control of the cGMP levels.
We here show that a GCAP2 functional transition from the
Ca2+-free to the Ca2+-loaded form is essential for photo-
receptor cell integrity, by a non-related mechanism. We
show that GCAP2 locked in its Ca2+-free form is retained by
phosphorylation and 14-3-3 binding to the proximal rod
compartments, causing severe cell damage. This study
identifies a pathway by which a sustained reduction in
intracellular free Ca2+ could result in photoreceptor
damage, relevant for light damage and for those genetic
disorders resulting in ‘‘equivalent-light’’ scenarios.
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had a higher relative level of expression (3.85:1 ratio), Fig. 1B and
Fig. S1, see Methods.
To assess whether bEF2GCAP2 expression in rods causes
compensatory changes in the expression levels of other proteins
involved in cGMP metabolism, we compared the level of
expression of PDE6 and Ret-GCs in retinal homogenates from
wildtype and transgenic mice from lines A and B (Fig. 1C). Levels
of PDEa, b and c subunits, or GC1 and GC2 were mostly
Figure 1. Transgene expression of bEF2GCAP2 in rods leads to retinal degeneration. A. Design of transgene expression vector. The cDNA
of bovine GCAP2 with the three functional EF hands disrupted [GCAP2 (E80Q, E116Q, D158N) or bEF2GCAP2] was expressed under the mouse opsin
promoter (MOP), with the polyadenilation signal of the mouse protamine 1 (MP1) gene. B. Western showing the level of expression of the transgene
in bGCAP2 line E and bEF2GCAP2 lines A and B, compared to wildtype mice. Equivalent fractions of a retina were resolved by SDS-PAGE from wt
(22 d of age), line E (40 d) and lines A (40 d) and B (22 d, showed from independent gel). An earlier time point was chosen for the strongest line (B) to
reduce the effect that its rapid retinal degeneration has on total retinal protein content. Bovine and murine GCAP2 differ in size by three amino acids
and can be distinguished by mobility. C. Compensatory changes in proteins involved in cGMP metabolism were not observed. The levels of PDEa,b
and c subunits, or GC1 and GC2 were mostly unaffected in mice from line A, whereas a reduction in all proteins was observed in line B at 22 d of age,
due to the shortened outer segments in this line. D. Light micrographs of retinal sections from mice expressing bGCAP2 (line E) or bEF2GCAP2
transgene (lines A and B) in the GCAPs+/+ background at 40 d or 3 m.
doi:10.1371/journal.pgen.1004480.g001
Figure 2. Transgenic expression and rate of retinal degeneration in the GCAPs2/2 background. A. Levels of transgene expression in the
GCAPs2/2 background in mouse retinas from line E (ctrl bGCAP2) and lines A, B (bEF2GCAP2). Equal fractions of the retina were loaded from mice at
30 d of age. Transgene expression levels estimated in the GCAPs+/+ background were maintained in the GCAPs2/2 background. B. Light
micrographs of retinal sections from mice of the indicated genotypes at 1, 3 and 5 months of age, standard cyclic light rearing. Lines A and B show a
progressive retinal degeneration in the GCAPs2/2 background, that reduces the ONL thickness to 4–5 rows of nuclei at three months, and to 3 rows
at five months (line A) or to a single row by five months of age (line B).
doi:10.1371/journal.pgen.1004480.g002
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unaffected in mice from line A, whereas a reduction in all proteins
was observed in line B at postnatal day 22 (p22), which can be
explained by the dramatic shortening and disorganization of rod
outer segments observed from a very early age in this line (Fig. 1D).
Mice expressing bEF2GCAP2 showed a progressive retinal
degeneration whose severity correlated with the level of expression
of the transgene. Figure 1D shows normal retinal morphology in
the control transgenic line E at p40 and at 3 months of age. In
contrast, clear signs of retinal degeneration were observed in mice
expressing bEF2GCAP2 from lines A and B. Mice from line B,
which express the highest levels of bEF2GCAP2, presented a
substantial shortening of rod outer segments and a noticeable
reduction of outer nuclear layer (ONL) thickness as early as p40,
with ONL thickness reduced to 6–7 rows of nuclei. Mice from line
A showed a slower progression of the disease, noticeable at 3
months, when the ONL thickness was reduced to 7–9 rows of
nuclei.
Because expression of wildtype bGCAP2 did not cause retinal
degeneration for up to one year of age in line E (results not shown),
the retinal degeneration observed in mice from lines A and B likely
results from distinctive properties of the mutant form of GCAP2
impaired to bind Ca2+. However, due to the different transgene
expression levels, we could not exclude that the observed
phenotype may result from overexpression of bGCAP2. To rule
out this possibility, we bred the control line E to homozygosity, to
obtain a line that expressed bGCAP2 to equivalent levels as
mutant line A. This line showed normal outer segment length and
organization, as well as normal outer nuclear layer thickness for up
to six months of age when raised in cyclic light [34]. From these
results we conclude that mutations that impair Ca2+ binding in
GCAP2 lead to retinal degeneration in vivo.
Retinal degeneration by bEF2GCAP2 is reproduced in the
GCAPs 2/2 background, and correlates with the loss of
visual function
In order to study the effects of the mutant protein on cell
physiology, we bred the transgenic lines to GCAPs2/2 mice, to
obtain expression of bEF2GCAP2 or control bGCAP2 in the
absence of the endogenous protein.
The relative levels of expression of the transgene in the
independent transgenic lines were maintained in the GCAPs2/2
background (Fig. 2A). Expression of bEF2GCAP2 in the
GCAPs2/2 background slightly accelerated the rate of retinal
degeneration observed in the GCAPs+/+ background. Mice from
the control lines GCAPs2/2 and GCAPs2/2 bGCAP2 E
showed largely normal retinas with an outer nuclear layer (ONL)
thickness of 10 rows of nuclei for up to 5 months of age (Fig. 2B),
and preserved normal visual function when raised in cyclic light
conditions as assessed by electroretinogram (ERG) [34]. In
contrast, GCAPs2/2 expressing bEF2GCAP2 showed a pro-
gressive retinal degeneration that correlated with loss of visual
function (Fig. S2). In retinas from line B the ONL was reduced to
six rows of nuclei and outer segments were much shorter than
normal as early as p30 (Fig. 2B), when the A and B-wave
amplitudes of ERG responses were half the size of normal
responses from littermate controls (not shown). At 3 months of age
the ONL was reduced to 4 rows of nuclei, and by 5 months it was
limited to a single row. Mice were unresponsive to light (flat ERG
traces) by 7 months (Fig. S2). A slightly slower retinal degeneration
was observed in mice from line A that went from a normal outer
nuclear layer thickness of 12 rows of nuclei at p30 to about 5 rows
by 3 months of age. ERG responses of these mice resembled
normal responses at very early ages, but A- and B-wave amplitudes
were reduced by half by 4 months, correlating with a dramatic cell
loss in these mice between p20 and 5 months of age (Fig. 2B and
Fig. S2). Most of these mice are non responsive to light by ERG by
7–8 months (Fig. S2).
bEF2GCAP2 protein accumulates in inactive form at the
inner segment of the cell
In vitro studies have shown that recombinant bEF2GCAP2
leads to maximal activation of Ret-GCs in reconstitution studies
Figure 3. Guanylate cyclase activity in retinal homogenates of
transgenic mice at 0 mM [Ca2+] and 2 mM [Ca2+]. Guanylate cyclase
activity (pmol cGMP/min.mg prot) was determined in WT, GCAPs2/2,
GCAPs2/2 bGCAP2 line E and GCAPs2/2 bEF2GCAP2 line A retinal
extracts at 0 mM [Ca2+] or 2 mM [Ca2+] conditions, in the absence or
presence of 3 mM recombinant GCAP2. In WT retinal homogenates at
0 mM [Ca2+] the endogenous GCAPs activate RetGC activity about 8-fold
over the activity at 2 mM [Ca2+]. This stimulation of RetGC activity at
0 mM [Ca2+] is lost in GCAPs2/2 retinal homogenates, but restored in
the GCAPs2/2 bGCAP2 line E, which indicates that the control bGCAP2
protein expressed in vivo as a transgene is active in these assays.
However, retinal homogenates from GCAPs2/2bEF2GCAP2 line A mice
showed greatly reduced RetGC activity at 0 mM [Ca2+] and no activity at
2 mM [Ca2+] conditions. Addition of 3 mM recombinant GCAP2 elicited
activation of RetGC at 0 mM [Ca2+] in all retinal homogenates, indicating
the presence of functional RetGC in all samples. These results show that
bEF2GCAP2 was present, but mostly inactive, in GCAPs2/2bEF2GCAP2
line A retinal homogenates. Results show the mean and standard
deviation of at least four independent experiments.
doi:10.1371/journal.pgen.1004480.g003
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using washed bovine rod outer segment membrane preparations
independently of free Ca2+ in the whole physiological range of
[Ca2+] [38]. To assay whether the transgenic bEF2GCAP2
protein has the capacity to activate Ret-GC activity in retinal
extracts from mice in a similar manner as in in vitro studies we
performed guanylate cyclase activity assays in retinal extracts from
the mutant or control mice obtained prior to significant retinal
degeneration -between p20 and p30 - under conditions of 0 Ca2+
or 2 mM Ca2+ (Fig. 3). Ca2+-dependent modulation of Ret-GC
activity was observed in retinal homogenates from wildtype mice
and control GCAPs2/2 bGCAP2 E line. As expected, the Ca2+-
sensitive guanylate cyclase activity was undetectable in
GCAPs2/2 retinal extracts, indicating that the guanylate cyclase
activity that is measurable in whole mouse retinal extracts
originates essentially from photoreceptor cells in a GCAPs-
dependent manner. As a control for the presence of functional
Ret-GCs in retinal extracts, guanylate cyclase activity was also
measured after addition of 3 mM recombinant bGCAP2, which
restored robust activity in a Ca2+ dependent manner. Surprisingly,
retinal extracts from GCAPs2/2 bEF2GCAP2 B mice resem-
bled those of GCAPs2/2. They showed little detectable retGC
activity at either 0 Ca2+ or high Ca2+. Even though the levels of
Ret-GCs and bEF2GCAP2 were reduced to some extent in these
retinal extracts due to the shortening of the rod outer segments in
this line, the addition of recombinant bGCAP2 showed that there
was functional Ret-GCs in these extracts at levels that were
sufficient to elicit a measurable activity. The results shown are the
average of four independent experiments. These results indicate
that while the transgenic bGCAP2 control protein expressed in the
GCAPs2/2 background reproduced normal activity, the trans-
genic mutant form of bGCAP2 impaired to bind Ca2+ showed
very little detectable activity in vivo.
To study whether the bEF2GCAP2 protein reproduced the
localization pattern of endogenous GCAP2 in transgenic mice, we
immunostained GCAP2 in retinal cryosections. Whereas trans-
genic bGCAP2 in the control line mimicked the localization of
endogenous GCAP2 in wildtype retinas (staining the outer
segment, inner segment, cytosol of outer nuclear layer and outer
plexiform layers of the retina, with the signal being most intense at
rod outer segments); this pattern was shifted in the case of
bEF2GCAP2, with the signal being most intense at the rod
proximal compartments, particularly at the inner segment layer
(Fig. 4). These results show that bEF2GCAP2, when expressed in
the GCAPs2/2 background, tend to accumulate at the metabolic
compartment of the cell.
These results indicate that bEF2GCAP2 in the retinas of
transgenic mice has a greatly reduced capacity to activate the
cyclase and accumulates at the inner segment of the cell, indicating
that the pathology in these mice does not result from unabated
cGMP synthesis. Furthermore, the retinal degeneration in
bEF2GCAP2 mice could not be prevented by raising the mice
in constant light exposure that would counteract the increase in
cGMP synthesis by continuous cGMP hydrolysis (Fig. S3), as was
the case in Y99C-GCAP1 mice [26].
Taken together, these results point to a mechanism independent
of cGMP metabolism as the molecular basis for the neurodegen-
eration in these mice.
bEF2GCAP2 protein is phosphorylated to high levels in
vivo and binds to 14-3-3 in a phosphorylation-dependent
manner
We reasoned that the accumulation of bEF2GCAP2 at the
proximal compartments of the cell rather than its absence at the
rod outer segment was the cause of the progressive retinal
degeneration in these mice, given that the absence of GCAP1 and
GCAP2 in GCAPs2/2 mice does not affect gross retinal
morphology [11]. To address why bEF2GCAP2 fails to be
distributed to the rod outer segment and how its retention and
accumulation at the inner segment leads to toxicity, we
investigated the protein-protein interactions that the mutant form
of the protein establishes in a specific manner. Immunoprecipi-
tation assays were conducted with an anti-GCAP2 monoclonal
antibody cross-linked to magnetic beads, using Triton X100-
solubilized whole retinal extracts from GCAPs2/2 bGCAP2 E
and GCAPs2/2 bEF2GCAP2 B mice. Retinal extracts from
GCAPs2/2 mice were carried to define the background. The
pool of proteins immunoprecipitated in each case was identified by
directly subjecting the elution fractions to trypsin-digestion and
liquid chromatography-tandem mass spectrometry analysis (LC-
MS/MS). We searched for proteins identified in the GCAPs2/2
bEF2GCAP2 B sample with an spectral counting at least 1.5-fold
over the GCAPs2/2 bGCAP2 and GCAPs2/2 control lines).
We found that only the distinct isoforms of 14-3-3 proteins fulfilled
Figure 4. bEF2GCAP2 mislocalizes in transgenic retinas, accumulating at the inner segment compartment of the cell. Cryosections of
central retina from WT, GCAPs2/2, GCAPs2/2 bGCAP2 line E and GCAPs2/2 bEF2GCAP2 line B, immunostained with an anti-GCAP2 polyclonal Ab.
Endogenous GCAP2 in WT retinas distributes to the cytosolic space of rod cells, at the rod outer segment, inner segment, outer nuclear and outer
plexiform layers of the retina. This pattern of staining is lost in GCAPs2/2 retinas and restored in GCAPs2/2bGCAP2 line E retinas. However, in
GCAPs2/2 bEF2GCAP2 line B the pattern of staining is shifted, with the GCAP2 signal being much stronger at the inner segment and proximal
compartments of the cell than at the outer segment. os, outer segment; is, inner segment; onl, outer nuclear layer.
doi:10.1371/journal.pgen.1004480.g004
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these criteria, being identified with a considerably higher number
of peptides [1.33 to 3.2-fold higher] in the GCAPs2/2bEF2G-
CAP2 B than in control samples in at least two independent
experiments (Table 1). Spectral counting of 14-3-3 isoforms were
between 1.6-fold and 5-fold higher in the GCAPs2/2bEF2G-
CAP2 B samples than in control samples in the two experiments
(Table S1).
Because 14-3-3 proteins typically bind to their targets in
response to phosphorylation [39], and since phosphorylation of
GCAP2 has been reported to occur in vitro at a conserved Ser at
position 201 in bGCAP2 [30], we next assayed whether the
binding of 14-3-3 to GCAP2 was phosphorylation dependent. We
first reproduced the observation that GCAP2 can be phosphor-
ylated in vitro by PKG, with Ca2+-free bGCAP2 being a better
substrate for the kinase than Ca2+-loaded bGCAP2 (Fig. 5A).
Subsequently, we used recombinant bGCAP2 or bEF2GCAP2 in
in vitro phosphorylation reactions with PKG to generate
phosphorylated-bGCAP2 or mock-treated bGCAP2 for pull-down
assays with bovine whole retinal homogenates (Fig. 5B). As seen in
Fig. 5C, 14-3-3 showed preferential binding to the phosphorylated
form of bGCAP2 or bEF2GCAP2 in two independent experi-
ments.
The observations that 14-3-3 binds more efficiently to bEF2G-
CAP2 than to bGCAP2 in vivo and that 14-3-3 binds to bGCAP2
in a phosphorylation dependent manner, together with the
reported higher efficiency of GCAP2 phosphorylation in its
Ca2+-free rather than its Ca2+-bound conformational state led us
to hypothesize that bEF2GCAP2 might be abnormally phosphor-
ylated in the living cell. To test this hypothesis we performed a 32Pi
-metabolic labeling of GCAPs2/2 bGCAP2 and GCAPs2/2
bEF2GCAP2 retinas in situ, followed by GCAP2 immunoprecip-
itation and SDS-PAGE analysis. Following the incorporation of
32Pi into the retinas of dark-adapted mice for 2 h, retinas were
either kept in darkness or exposed to 5 min of bright white light
and immediately subjected to Triton X100-solubilization and
GCAP2 immunoprecipitation. GCAPs2/2 retinas were carried
as a negative control.
Fig. 6A shows equal fractions of the Triton X100-solubilized
retinas after 32Pi-incorporation and 5 min dark- or light-exposure.
The overall pattern of bands in this panel shows that incorporation
of 32Pi into the ATP pool of the retina occurred at comparable levels
in all samples, allowing the detection of phosphorylated proteins
and changes in the overall phosphorylation pattern caused by light
(e.g. the light-dependent phosphorylation of rhodopsin is observed
at 35–37 kDa). GCAP2 phosphorylation could not be detected in
whole retinal extracts, so these samples were used as inputs for the
GCAP2 immunoprecipitation assay shown in Fig. 6B. GCAP2 was
phosphorylated to low levels in the GCAPs2/2 bGCAP2 sample
in the dark, and to a slightly higher extent when the retina was
exposed to light. No 24 kDa bands were observed in the
GCAPs2/2 samples. Strikingly high levels of bEF2GCAP2
phosphorylation were observed in GCAPs2/2 bEF2GCAP2
samples (lines A and B). A GCAP2 immunoblot of the 32P-labeled
membrane confirmed that comparable levels of GCAP2 were
immunoprecipitated in GCAPs2/2 bGCAP2 and GCAPs2/2
bEF2GCAP2 samples (Fig. 6C). Fig. 6D shows the subsequent
immunostaining of the 14-3-3 pan and epsilon isoforms in the same
membrane, further confirming the selective binding of 14-3-3 to the
phosphorylated mutant form of GCAP2 impaired to bind Ca2+.
GCAP2 phosphorylation was further characterized by isoelec-
trofocusing gel analysis followed by immunoblotting with a
GCAP2 antibody (Fig. 7). Under room light conditions wildtype
C57/B6 mice showed two bands of roughly equal intensity
corresponding to the pI of the unphosphorylated (4.92) and singly
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phosphorylated (4.85) mGCAP2. The intensity of the 4.85 band
was greatly diminished when NaF, a broad phosphatase inhibitor,
was omitted from the samples, thus confirming the identity of this
band as phosphorylated GCAP2 (Fig. 7A). We conclude that
about half of the total GCAP2 protein is phosphorylated in
wildtype mice under standard room light conditions. The extent to
which endogenous mGCAP2 was phosphorylated in wildtype mice
under room light conditions was higher than that of bGCAP2 in
GCAPs2/2 bGCAP2 transgenic mice.
To address whether GCAP2 phosphorylation takes place
differentially in dark/light conditions, wildtype mice that were
adapted to room light for 1 h were dark-adapted for up to 14 h,
and GCAP2 phosphorylation was analyzed at 1, 2, 3, 5 and 14 h.
Fig. 7B shows that the ratio of unphosphorylated to phosphory-
Figure 5. The protein 14-3-3 binds to recombinant GCAP2 in a phosphorylation-dependent manner. A. In vitro, Ca2+-free bGCAP2 is
phosphorylated more efficiently than Ca2+-bound bGCAP2. Upper panel shows an autoradiograph of 33P phosphorylation products from an in vitro
phosphorylation reaction of recombinant wildtype bGCAP2 or bEF2GCAP2 with protein kinase G (PKG), in the presence or absence of free Ca2+. The
20 ml reaction mixture contained 8.5 mg of purified recombinant wildtype bGCAP2 or bEF2GCAP2, purified PKGIa (100 units, Calbiochem) and 3 mCi
of 33P- cATP in phosphorylation reaction buffer, containing either CaCl2 or EGTA (see Methods). After incubation, reaction mixtures were resolved by
15% SDS-PAGE and transferred to a nitrocellulose membrane. Lower panel shows immunostained GCAP2. Recombinant bGCAP2 or bEF2GCAP2
protein were present to similar amounts in all reaction tubes. B. In vitro phosphorylated or mock-treated bGCAP2 and bEF2GCAP2 were generated
for pull-down assays. Phosphorylation reactions were performed as above, in the presence of EGTA, except that cGMP was added to 500 mM (+ lanes)
or not added (2 lanes). Immunostaining of GCAP2 in the same nitrocellulose membrane shows the GCAP2 monomer at 25 kDa and upper bands
corresponding to dimers and multimers of GCAP2, observed to a higher extent in the EF2GCAP2 lanes. Molecular mass (MW) markers (Precision Plus
Protein Standards, BioRad) are 20, 25, 37, 50, 75, 100 and 150 kDa. Experiment shown in duplicate. C. The 14-3-3 protein isoforms bind more
efficiently to phosphorylated bGCAP2 and bEF2GCAP2 than to unphosphorylated counterparts. Phosphorylated or mock- proteins were cross-liked
to magnetic beads and pull-down assays were performed with whole bovine retinal extracts obtained in 1% Triton-X100. Panels show the input and
bound fractions for the indicated phospho- or mock-proteins, resolved by 15% SDS-PAGE. Membrane was sequentially incubated with a pAb to 14-3-
3pan (IBL International, Hamburg, Germany), a mAb to 14-3-3e (abcam, Cambridge, UK), an IRDye 800CW Goat Anti-rabbit IgG and a IRDye 680CW
Goat Anti-mouse IgG (Tebu-Bio, Offenbach, Germany). Image was acquired at the Odyssey Imaging System (LI-COR). Therefore 14-3-3pan isoforms
(30 kDa) are shown in green, while 14-3-3e (33 kDa) is shown in red. Experiment shown in duplicate.
doi:10.1371/journal.pgen.1004480.g005
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Figure 6. 32Pi metabolic labeling reveals phosphorylation of bEF
2GCAP2 to a higher extent than bGCAP2 in living retinas. A. In situ
phosphorylation assay. Retinas from dark-adapted mice from the indicated phenotypes were dissected under dim red light, incubated in bicarbonate
buffered Locke’s solution containing 1 mCi/mL of 32P-H3PO4 for 90 min in a 5% CO2 incubator and exposed to white light for 5 min (L) or maintained
in darkness (D). Retinas were homogenized in Triton X100-solubilization buffer and pre-cleared by centrifugation. Aliquots corresponding to one
tenth of a retina were resolved by 15% SDS-PAGE and blotted to a nitrocellulose membrane. Phosphorylated proteins were visualized by
autoradiography upon 4 h of exposure. B. GCAP2 immunoprecipitation in 32P-labeled samples. Solubilized samples corresponding to two retinas per
phenotype and condition were used as inputs for GCAP2 immunoprecipitation with an anti-GCAP2 mAb. Elution fractions were resolved by 15% SDS-
PAGE, blotted to a nitrocellulose membrane and visualized by autoradiography after 4 days of exposure. C. Western blot of samples in (B) using a
polyclonal antibody anti-GCAP2 show that the amount of GCAP2 in the control GCAPs2/2 bGCAP2 E line was comparable to that in mutant lines
GCAPs2/2 bEF2GCAP2 A and B. D. Immunostaining of 14-3-3 proteins in the same membrane, by using a pAb to 14-3-3pan (IBL International,
Hamburg, Germany).
doi:10.1371/journal.pgen.1004480.g006
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lated GCAP2 did not vary substantially during the 14 h dark-
adaptation period. If we presume that GCAP2 is preferentially
phosphorylated during periods of light exposure when in its Ca2+-
free conformation, these results may indicate that a few hours of
dark- or light-adaptation are not enough to have a noticeable
effect on the overall GCAP2 population. This would not be
surprising if only newly synthesized GCAP2 was subjected to the
kinase/phosphatase regulation (see Discussion).
Isoelectrofocusing of retinal samples from GCAPs2/2
bEF2GCAP2 and GCAPs2/2 bGCAP2 were performed to
assay the steady-state relative levels of non-phosphorylated and
phosphorylated GCAP2 (Fig. 7C). Whereas endogenous GCAP2
in wildtype C57/B6 mice showed similar proportions of non-
phosphorylated and phosphorylated GCAP2, the GCAPs2/2
bEF2GCAP2 sample showed a larger fraction of phosphorylated
GCAP2 and the GCAPs2/2 bGCAP2 sample showed the
reverse: a larger fraction of non-phosphorylated GCAP2. These
results are consistent with the metabolic labeling results, namely,
low levels of phosphorylation in the GCAPs2/2 bGCAP2 control
line, and much higher phosphorylation levels in the GCAPs2/2
bEF2GCAP2 line (Fig. 7C and Fig. 6B).
To address whether 14-3-3 binding to phosphorylated GCAP2
might be the cause of its retention at inner segments, we analyzed
the localization of the 14-3-3 proteins in retinal sections from
GCAPs2/2 bGCAP2 and GCAPs2/2 bEF2GCAP2 samples.
Fig. 8 shows that 14-3-3 epsilon localizes to all cell layers of the
retina; the ganglion cell layer, the inner cell layer and the
photoreceptor cell layer of the retina. In photoreceptor cells it
appears to distribute to the inner segment, the perinuclear region
and the synaptic terminal, but it is excluded from the outer
segment. This isoform of 14-3-3 colocalized with GCAP2 mainly
at the inner segment of GCAPs2/2 bGCAP2 samples, but also to
the perinuclear region and synaptic terminals in the GCAPs2/2
bEF2GCAP2 samples. From these results we infer that the
localization pattern of 14-3-3e in photoreceptor cells would be
consistent with a role of GCAP2 phosphorylation and 14-3-3
binding at retaining the mutant form of GCAP2 impaired to bind
Ca2+ at the proximal compartments of the cell.
Phosphorylation at Ser201 is required for the retention of
bEF2GCAP2 at the proximal compartments of the
photoreceptor cell in vivo
To address whether phosphorylation of GCAP2 is what causes
the retention of bEF2GCAP2 at the inner segment and proximal
compartments of the cell, we expressed a mutant form of
bEF2GCAP2 in which Ser201 was mutated to Gly as a transient
transgene in rod cells, given that Ser201 is the only residue that
was found to be phosphorylated in GCAP2 [30].
The bS201G/EF2GCAP2 cDNA was expressed under the rod
opsin promoter by subretinal injection and in vivo electroporation
of the DNA in neonatal GCAPs2/2 mice as described [40]. Both
bGCAP2 and bEF2GCAP2 cDNAs were carried out in parallel in
order to compare the localization of the mutants under equivalent
experimental conditions. A plasmid expressing the green fluores-
cent protein (GFP) under the Ubiquitin C promoter was coinjected
to identify the region around the injection site in which DNA
transfection was efficient, and electroporated retinas were
analyzed at p28.
Figure 7. Analysis of GCAP2 phosphorylation by isoelectrofo-
cusing. A. Isoelectrofocusing (IEF) gel of light-adapted wildtype mouse
retinal homogenates. Mice were light-adapted to room light. Retinas
were obtained, solubilized in a saline buffer with 1% dodecyl maltoside,
in the presence or absence of 50 mM NaF (phosphatase inhibitor).
Samples were clarified, loaded onto an electrofocusing gel (pH range 3–
8) and focused for 2 h at 23W. Proteins were transferred to a
nitrocellulose membrane and incubated with an anti-GCAP2 Ab. Two
prominent bands are observed at 4.92 and 4.85 isoelectric point, that
correspond to unphosphorylated and monophosphorylated mGCAP2,
respectively. B. The overall phosphorylation status of GCAP2 does not
change significantly during a 12 h period of dark-adaptation. Mice were
light-adapted to room light for 1 h, and subjected to dark-adaptation
for a period of up to 14 h. Retinas were analyzed as above. C. Analysis
of GCAP2 phosphorylation status in the indicated mouse lines.
Transgenic bGCAP2 is phosphorylated to a lesser extent than the
endogenous mGCAP2, whereas bEF2GCAP2 is phosphorylated to a
much higher extent. Note that the isoelectric point of bGCAP2 differs
from that of mGCAP2, and that the isoelectric point of bEF2GCAP2
(E80Q,E116Q,D158N GCAP2) is shifted versus that of bGCAP2. Results
from the isoelectrofocusing gels confirm that transgenic bEF2GCAP2 is
phosphorylated to a much higher extent than the control transgenic
bGCAP2.
doi:10.1371/journal.pgen.1004480.g007
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Fig. 9 shows that the localization of bGCAP2 and bEF2GCAP2
in the transient transgenic mice obtained by electroporation
reproduced the localization observed in stable transgenics:
specifically, bEF2GCAP2 was retained at the inner segment and
proximal compartments of transfected photoreceptors. bEF2G-
CAP2 was excluded from the outer segment, which is demarcated
by rhodopsin immunofluorescence (red) (Fig. 9 panels E, F and
profile from cell N.6, Fig. S4 for additional images and profiles). In
contrast, the mutant bS201G/EF2GCAP2 distributed to the
proximal compartments of the cell but also to rod outer segments.
As shown in panels H-I of Fig. 9 and in the profile from cell N. 10,
the GCAP2 signal -in green- co-labeled with rhodopsin (red) in all
transfected cells (thirteen cells analyzed, 57% of GCAP2 signal co-
labeled with rhodopsin on average, see Fig. S4), indicating its
redistribution to rod outer segments. On average, 50% of the
protein distributed to rod outer segments when bGCAP2 was
expressed, whereas virtually all bEF2GCAP2 was retained at the
inner segment and proximal compartments. Mutating S201 to Gly
in bEF2GCAP2 reverted this retention, resulting in 57% of the
protein distributing to rod outer segment (histogram in Fig. 9J).
These results indicate that phosphorylation at Ser201 in the
mutant form of GCAP2 impaired to bind Ca2+ is what causes its
accumulation at the inner segment and proximal compartments of
the cell, ultimately leading to toxicity.
Light conditions expected to promote a sustained
reduction in the concentration of Ca2+ at the inner
segment compartment lead to GCAP2 retention at the
inner segment in wildtype mice
The finding that GCAP2 locked in its Ca2+-free form (bEF2G-
CAP2) is retained at the inner segment compartment resulting in
Figure 8. Coimmunolocalization of 14-3-3e with GCAP2 in retinas from GCAPs2/2bGCAP2 E and GCAPs2/2 bEF2GCAP2 B mice.
Cryosections of central retina from the indicated lines at 20 days of age were immunostained with an anti-GCAP2 mAb (Affinity Bioreagents, Golden,
Colorado, USA) and an anti-14-3-3e rabbit monoclonal (abcam, Cambridge, UK), by indirect immunofluorescence staining with the Alexa 488 goat
anti-rabbit IgG and Alexa 555 goat anti-mouse IgG (Molecular Probes, Eugene, Oregon). GCAP2 signal in red, 14-3-3e signal in green. GCAP2 and 14-3-
3 proteins colocalize at the inner segment and proximal compartments of photoreceptor cells.
doi:10.1371/journal.pgen.1004480.g008
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toxicity could have important implications for disease, if it meant
that endogenous Ca2+-free GCAP2 would be retained at the inner
segment in wildtype mice during conditions that promoted a
sustained reduction in [Ca2+]i. Mutations in several genes involved
in the light response result in the sustained hyperpolarization of
the cell and a steady reduction in [Ca2+]i. Null mutations in
GUCY2D or RD3 causative of the Lebers Congenital Amaurosis
(LCA) form of blindness, for instance, would result in reduced
levels of cGMP at the rod outer segments, the closure of cGMP-
channels and hyperpolarization of the cell, with the ensuing
reduction in the influx of Ca2+ to rod inner segment [36,37,41].
Also associated to LCA, null mutations in RPE65 result in retinal
Figure 9. Mutation of Ser201 in bEF2GCAP2 precludes protein retention at the inner segment. Wildtype bGCAP2, bEF2GCAP2 or
bS201G/EF2GCAP2 were transiently expressed in the rod photoreceptor cells of GCAPs2/2 mice by in vivo DNA electroporation of neonates
following subretinal injection. A plasmid expressing GFP driven by the Ubiquitin C promoter was coinjected in order to identify transfected areas in
the eye at postnatal day 28 (p28). Cryosections were immunostained for GCAP2 with a polyclonal GCAP2 Ab and an Alexa Fluor 555 anti-rabbit IgG
(signal converted to green); and for rhodopsin with monoclonal Ab 1D4 and an Alexa Fluor 647 anti-mouse IgG (red signal). Transient expression of
wildtype bGCAP2 by electroporation reproduced the reported localization pattern in the stable transgenic line, namely, its almost equal distribution
between the inner and outer segments (panels A–C, profile for cell N.3). bEF2GCAP2 was mostly retained at the inner segments, being excluded from
outer segments (panels D–F, and profile for cell N.6), which also reproduced the observation from the stable bEF2GCAP2 transgenic lines. In contrast,
bS201G/EF2GCAP2 localized to some extent at the inner segment but mostly distributed to rod outer segments, showing a clear colocalization with
rhodopsin (panels G–I, and profile from cell N.10). Panel J shows a histogram of the mean percentage of GCAP2 distribution to ROS for each
phenotype and the standard error of the mean, as determined by calculating: (the intensity of GCAP2 that colocalizes with rhodopsin)/(intensity of
GCAP2 that colocalizes with rhodopsin + intensity of GCAP2 at the inner segment), see Methods. (Five cells were analyzed for the WT sample, twelve
cells for bEF2GCAP2 and thirteen cells for bS201G/GCAP2).
doi:10.1371/journal.pgen.1004480.g009
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degeneration due to the basal constitutive activity associated to
opsin, the apoprotein form of the visual pigment, leading to a
sustained hyperpolarization of the cell [42]. These genetic
disorders that ultimately cause an effect similar to continuous
light exposure, are collectively referred to as ‘‘equivalent-light’’
disorders [43]. Therefore, if GCAP2 was retained at the inner
segment under constant illumination conditions, it would be an
indication that this pathway could contribute to the pathology of
these disorders.
Wildtype mice were exposed to constant fluorescent light
(700 lux), or kept in dark cabinets for thirty days, and GCAP2
subcellular distribution was analyzed by immunofluorescence
(Fig. 10). The percentage of GCAP2 co-localizing with rhodopsin
was quantified in four mice per condition. After 30 days of light
exposure 84% of GCAP2 was retained at the inner segment, in
contrast to 45% of GCAP2 retained in mice kept for 30 d in
constant darkness, P#0,0001 (histogram Fig. 10).
These results show that a sustained drop in [Ca2+]i in wildtype
rod photoreceptors causes GCAP2 retention at the inner segment.
This, together with the results obtained from bEF2GCAP2
transgenic mice showing that accumulation of bEF2GCAP2 at
the inner segment results in toxicity, points to the sustained
retention of Ca2+-free GCAP2 at the inner segment as a pathway
that could contribute to the pathology of ‘‘light-equivalent’’
disorders.
Discussion
Precluding Ca2+ binding to GCAP2 in vivo leads to retinal
degeneration
We here report that a form of GCAP2 with mutations that impair
Ca2+ coordination at the three functional EF-loops (bEF2GCAP2)
led to retinal degeneration when expressed in rods in transgenic
mice. In vitro the bEF2GCAP2 mutant shows a similar shift in Ca2+
sensitivity of guanylate cyclase regulation as the Y99C, E155G and
other GCAP1 mutants that directly or indirectly affect Ca2+
coordination [22,24,38]. These GCAP1 mutants have been
demonstrated to cause retinal degeneration in vivo by leading to
persistent activation of the cyclase, causing elevated levels of cGMP
and Ca2+ [23,25,26]. Intriguingly, we found that the retinal
degeneration caused by bEF2GCAP2 expression in rods was
independent of cGMP metabolism. When guanylate cyclase activity
was measured in retinal homogenates from bEF2GCAP2 trans-
genic mice, instead of constitutive activation of the cyclase we found
very diminished cyclase activity independently of the [Ca2+]
conditions, which contrasts with the normal cyclase activity
observed in homogenates of wildtype and bGCAP2 control-
transgenic mice (Fig. 3). Furthermore, retinal degeneration in
bEF2GCAP2 transgenic mice could not be prevented or delayed by
raising the mice under constant light exposure (Fig. S3). These
results show for the first time that functional EF-hands in GCAP2
are required for photoreceptor cell integrity in vivo, by a
mechanism independent of guanylate cyclase regulation.
Phosphorylation of GCAP2 and 14-3-3 binding as a new
in vivo mechanism controlling GCAP2 subcellular
distribution that causes toxicity when overly deregulated
In contrast to the bGCAP2 control-transgenic protein that
reproduced the endogenous mGCAP2 subcellular localization,
bEF2GCAP2 largely accumulated at inner segment and proximal
compartments of the rod when it was expressed in the
GCAPs2/2 background (Fig. 4). At this compartment, bEF2G-
CAP2 was phosphorylated to a much higher extent than the
control transgenic protein in in situ phosphorylation assays as well
as under steady state conditions in the intact rod as shown by IEF,
and it was found to bind 14-3-3 proteins (Table 1, Figs. 5–7). This
constitutes the first report that GCAP2 is phosphorylated in vivo,
at much higher levels when locked in its Ca2+-free conformation,
and that phosphorylation of GCAP2 triggers 14-3-3 binding. We
show that 14-3-3 localization in rod photoreceptors is restricted to
proximal compartments and excluded from the outer segments
(Fig. 8). Furthermore, we demonstrate that phosphorylation is
required for bEF2GCAP2 retention at proximal compartments by
showing that replacing Ser201 by Gly in bEF2GCAP2 substan-
tially reverts this retention (Fig. 9). On average 57% of bS201G/
EF2GCAP2 localized to rod outer segments (Fig. 10 histogram
and Fig. S4, n = 13 cells). We believe that the reason that a 100%
reversion was not observed is that 14-3-3 shows some affinity for
unphosphorylated bEF2GCAP2 as well (Fig. 5). We therefore
infer that 14-3-3 binding to phosphorylated GCAP2 retains the
protein at proximal compartments, in what clearly represents an
important step in the regulation of GCAP2 subcellular distribution
in vivo, somewhat analogous to 14-3-3 regulation of phosducin
availability during dark and light adaptation.
14-3-3 proteins are a family of phosphobinding proteins of
about 30 kDa that comprises seven homologs in mammals. They
exist as homo- or hetero-dimers that are rigid in structure, with
each 14-3-3 dimer binding to two different phospho-binding sites
either in the same or in two independent target proteins. By
masking an epitope, clasping epitopes or promoting the scaffolding
of their clients, 14-3-3 proteins exert a diverse range of regulatory
roles in metabolism, trafficking or integration of cell survival versus
cell death pathways [39]. In the retina, 14-3-3 proteins interact
with phosducin at rod inner segments, regulating the amount of
free phosducin during dark- and light-adaptation [44,45].
Phosducin modulates the amount of Trabc heterotrimer through
competition with Gta subunit for binding to the Gtbc complex.
When light exposure activates Gt, releasing Gtbc from Gta at rod
outer segments, phosducin association to Gtbc facilitates Gta and
Pd-Gtbc independent translocation to the inner segment compart-
ment [46]. At the inner segment during dark-adaptation
phosducin is simultaneously phosphorylated at Ser-54 and Ser-
73 residues by PKA and CaMK, which causes a competing
interaction with the 14-3-3 protein that dramatically reduces
phosducin binding to Gtbc [47]. This allows the redistribution of
Gta and Gtbc to rod outer segments, the former assisted by
UNC119 and the latter by PrBP [48,49]. At rod outer segments Tr
subunits are discharged to membranes and a heterotrimer forms
again.
How 14-3-3 binding to phosphorylated GCAP2 fits with
GCAP2 overall role in photoreceptor cell physiology and inherited
retinal dystrophies is only emerging. It is clear from this work that
GCAP2 is phosphorylated preferentially in its Ca2+-free form in
vivo. Because it is well established that GCAP2 in its Ca2+-free
form forms dimers [29], and that 14-3-3 exists as dimers that bind
to two consensus binding sites in client proteins [39], it seems
straightforward to propose that a dimer of 14-3-3 would bind to a
dimer of GCAP2, presumably to stabilize it (Fig. 11). Because
GCAP1 and GCAP2, unlike recoverin or phosducin, were shown
not to redistribute between subcellular compartments during dark-
or light-adaptation [50], we deduce that this mechanism would
mainly affect the cytosolic distribution of newly synthesized
protein.
We propose a model in which the GCAP2 molecules
synthesized during the dark period (predominantly in the Ca2+-
loaded state) would bind to RetGC and be transported to rod
outer segments, whereas the GCAP2 molecules synthesized in the
light period (GCAP2 in its Ca2+-free state) would be phosphor-
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ylated and retained at proximal compartments by 14-3-3 binding
(Fig. 11). Such a scenario would result in the phosphorylation and
retention to proximal compartments of about 50% of GCAP2
molecules in a physiological situation (wildtype mice raised in
standard cyclic light). This is what we observe by IEF (Fig. 7) and
by immunolocalization analysis (Fig. 4). This model would also
explain why 12 h of dark-adaptation did not have a noticeable
effect on the steady-state phosphorylation levels of GCAP2 (Fig. 7).
The model would predict that wildtype mice reared under
constant light exposure for a period of time covering the complete
renewal of the rod outer segment would result in massive GCAP2
retention at the inner segment, given that GCAP2 would always
be synthesized in a context of low [Ca2+]i, and that is precisely
what we have observed after exposing mice to constant light for
30 days (Fig. 10). In contrast, it would be predicted that wildtype
mice reared in constant darkness would result in GCAP2 major
localization to the rod outer segment layer. This, however, was
not observed. In mice reared in darkness for 30 days GCAP2
distributed about equally between inner and outer segment
layers (Fig. 10). We interpret this result as an indication that
some of the protein interactions required for GCAP2 transport
to the rod outer segment (e.g. RetGC, RD3) might be rate-
limiting.
We propose that GCAP2 phosphorylation and 14-3-3 binding
constitute a major molecular determinant of GCAP2 subcellular
localization upon its synthesis. What is its physiological relevance?
A possibility is that 14-3-3 binding to GCAP2, by trapping
GCAP2 to proximal compartments, might work to secure a
reservoir of GCAP2 at these compartments, where GCAP2 may
be exerting other roles, e.g. at the synaptic terminal [34,35].
Alternatively, the 14-3-3 trapping of Ca2+-free GCAP2 upon its
phosphorylation might serve as a protein quality control mecha-
nism, to avoid that an excess of Ca2+-free, aggregation-prone
GCAP2 molecules would reach the rod outer segment. Irrespec-
tive of its physiological significance, this regulatory enzymatic step
is specific of GCAP2, given that GCAP1 is not phosphorylated,
and might have evolved because it is more relevant for rods than
cones. Conditions that substantially alter this regulatory mecha-
nism increasing the protein retention at the inner segment of the
Ca2+-free form would have toxic consequences for the cell. We
propose that toxicity in this scenario would arise from GCAP2
natural tendency to aggregate (see below).
Figure 10. Constant light exposure for 30 days retains endogenous GCAP2 at the inner segment in wildtype mice. A. Wildtype mice
(C57Bl/6J) were exposed to white fluorescent light of 700 lux intensity for 30 days (upper panel row), or kept in constant darkness for 30 days (lower
row). Cryosections of central retina were immunostained with an anti-GCAP2 pAb and an anti-rhodopsin mAb, by indirect immunofluorescence with
Alexa 488 goat anti-rabbit IgG and Alexa 555 goat anti-mouse IgG (molecular Probes, Oregon). GCAP2 signal in green, rhodopsin signal in red. B. Z-
axis stacks were obtained from four mice per condition, and the percentage of GCAP2 signal colocalizing with rhodopsin at the rod outer segment
layer was quantified by ImageJ (see Methods). Values for the percentage of GCAP2 co-localizing with rhodopsin were 54,60%61,47 (n = 4) in dark
samples, and 15,96%62,05 (n = 4) in light samples. Student T-test P,0,001 (GraphPad Prism 6).
doi:10.1371/journal.pgen.1004480.g010
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Physiological implications of GCAP2 phosphorylation and
14-3-3 binding for inherited retinal dystrophies
GCAP2 phosphorylation and 14-3-3 binding are observed to a
more moderate extent in the bGCAP2 control transgenic line (IEF
gel in Fig. 7) than in wildtype mice, presumably because bovine
GCAP2 is not such a good substrate for the murine kinase as the
endogenous murine GCAP2. In wildtype mice phosphorylated
GCAP2 at steady state constitutes about 50% of the total protein,
consistent with about 50% of the protein retention at rod proximal
compartments. This indicates that GCAP2 phosphorylation and
14-3-3 binding are not in itself toxic for the cell. It is therefore the
deregulation of this mechanism– when all GCAP2 molecules are
impaired to coordinate Ca2+ and GCAP2 phosphorylation and 14-
3-3 binding are happening to a much larger extent- that correlates
with severe retinal degeneration in the bEF2GCAP2 line.
How does the accumulation of GCAP2-14-3-3 complexes at the
rod inner segment lead to cell death? We hypothesize that
accumulation of these complexes might result in pathology due to
the formation of misfolded GCAP2 oligomers, in much a similar
way to which synuclein, APP, Tau, Huntingtin or ataxin lead to
neuronal cell death in Parkinson’s (PD), Alzheimer (AD),
Huntington’s (HD) or spinocerebellar ataxia (SCA) diseases.
GCAP2 shows a natural tendency to aggregate. Structural studies
have shown that the Ca2+-free form of GCAP proteins, and
particularly of GCAP2, are difficult to maintain in solution and are
prone to aggregation [51]. When expressed in bacteria,
recombinant GCAP2 accumulates in inclusion bodies, is only
solubilized at high concentrations of guanidinium or urea, and is
difficult to maintain in solution after refolding [1]. Dimers and
high molecular weight aggregates can typically be distinguished by
SDS-PAGE, more prominently for EF2GCAP2 than for the
wildtype form of the protein (e.g. this study, Fig. 5B). On the other
hand, previous studies have found a close association between 14-
3-3 and progressive neurodegenerative diseases. 14-3-3 proteins
have been shown to colocalize with AD neurofibrillary tangles that
are composed primarily of hyperphosphorylated tau proteins
[52,53]. In PD, 14-3-3 is detectable in Lewy bodies which
accumulate a-synuclein [54]; and 14-3-3 colocalization was also
reported for mutant ataxin in SCA [55]. Furthermore, 14-3-3 zeta
and epsilon binding to phosphorylated ataxin-1 at S776 was
shown to aggravate neurodegeneration by stabilizing mutant
ataxin, retarding its degradation and enhancing its aggregation in
transfected cells and transgenic flies [55]. The requirement of 14-
3-3 zeta for Htt86Q aggregate formation has also been established
in cells [56].
We propose that the mutant form of GCAP2 locked in its Ca2+-
free conformation results in toxicity in vivo by the progressive
formation of soluble high molecular weight oligomers of GCAP2-
14-3-3 that are toxic for the cell. Inclusion bodies were not
detected in our immunofluorescence assays with the polyclonal or
monoclonal anti-GCAP2 antibodies used, or the anti-14-3-3e
monoclonal antibody. It may happen that these antibodies do not
Figure 11. Model depicting a mechanism regulating GCAP2 distribution in rods involving GCAP2 phosphorylation and 14-3-3
binding. Under high Ca2+ conditions typical of the dark-steady state, the Ca2+-loaded form of GCAP2 would bind to Ret-GC and be transported to
rod outer segments (left sketch); whereas under low Ca2+ conditions (e.g. light periods), the Ca2+-free form of GCAP2 would be retained by 14-3-3 at
proximal compartments (middle). These alternating scenarios would result in approximately half of GCAP2 distributing to the inner segment and
proximal compartments of the cell, and half to the outer segment compartment in a physiological situation (e.g. in wildtype mice raised in standard
cyclic light). However, a prolonged light exposure or genetic conditions that would result in an abnormal accumulation of GCAP2 in its Ca2+-free form
(e.g. mutations in components of the phototransduction cascade causing unabated signaling, hyperpolarization of the cell and a sustained reduction
in [Ca2+]i at the inner segment) would lead to neurodegeneration likely by inducing GCAP2 aggregation, or by GCAP2-mediated toxicity some other
way (right sketch).
doi:10.1371/journal.pgen.1004480.g011
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recognize inclusion bodies, or that their absence would result from
a relatively efficient clearance of the mutant protein and therefore
slow formation of putative deposits. In this sense we have observed
that inhibition of the proteasome results in an increase of
EF2GCAP2 levels (Lo´pez-del Hoyo and Me´ndez, unpublished
observation).
This mechanism of toxicity caused by GCAP2 misfolding may
contribute to the pathology of genetic mutations causing
‘‘equivalent-light damage’’ that result in a sustained reduction in
the level of intracellular Ca2+: e.g. mutations in the visual cycle
resulting in opsin basal constitutive activity (e.g. null mutations in
RPE65 [42]). Furthermore, this mechanism of toxicity is likely to
contribute to cell death and retinal degeneration in those cases of
Lebers Congenital Amaurosis (LCA) in which two conditions
converge: GCAPs accumulation at the inner segment and a
sustained reduction in the level of intracellular Ca2+. Those
conditions are met, for instance, in LCA1 caused by null mutations
in RetGC-E (GUCY2D) or LCA12 caused by mutations in RD3,
two severe and prevalent inherited retinal dystrophies.
In conclusion, we propose that GCAP2 may be a mediator of
‘‘equivalent-light’’ genetic damage, by its natural tendency to
aggregate when in its Ca2+-free form, in a process regulated by
phosphorylation and 14-3-3 binding. Future studies will be
addressed at further characterizing the stoichiometry, solubility
and turn-over of GCAP2-14-3-3 complexes, as well as their effects
on the normal functions of the cell.
Materials and Methods
Transgenic expression of bEF2GCAP2 in mouse rods and
determination of transgene expression levels by western
blot
This study was conducted in accordance with the ARVO
statement for the Use of Animals in Ophthalmic and Vision
Research and in compliance with Acts 5/1995 and 214/1997 for
the welfare of experimental animals of the Autonomous Commu-
nity (Generalitat) of Catalonia, and approved by the Ethics
Committee on Animal Experiments of the University of Barcelona
and the University of Southern California. The GCAP2 expres-
sion vectors used to generate transgenic mice were obtained by
assembling the 4.4 kb mouse opsin promoter with bovine wildtype
GCAP2 cDNA or mutant bEF2GCAP2 [GCAP2 E80Q/E116Q/
D158N, [38]] cDNA (0.7 kb), and a 0.6 kb fragment containing
the mouse protamine 1 polyadenylation sequence, into pBluescript
II SK (Stratagene, La Jolla, California). The resulting fusion gene,
5.7 kb in size, was excised from the plasmid, gel purified and
microinjected at 1 mg/ml into the pronuclei of C57Bl6/J6DBA/
2J F1 hybrid mouse embryos (The Jackson Laboratories, Bar
Harbor, Maine). Injected embryos were implanted into pseudo-
pregnant females, and progenie was screened for founders by PCR
amplification of tail genomic DNA with primers:
Rh1.1: 59GTGCCTGGAGTTGCGCTGTGGG39 (forward)
and p24: 59TGGCCTCCTCGTTGTCCGGGACCTT39 (re-
verse).
Founder mice were bred to C57Bl6 mice to maintain the
transgene in a pigmented wildtype genetic background, or to
GCAPs2/2 to generate GCAPs2/2 bEF2GCAP2 mice. To
detect transgenic GCAP2 expression by immunoblot, retinas from
mice of each genotype were obtained at either postnatal day 22
(p22) (for WT and mice from line B) or p40 (lines A and E), and
were homogenized in 100 ml of homogenization buffer [80 mM
TrisHCl, pH 8.0, 4 mM MgCl2, 0.5 mg/ml Pefabloc SC,
0.5 mg/ml Complete Mini protease inhibitors (Roche, Basel,
Switzerland)]. After addition of SDS Laemmli sample buffer,
samples were boiled for 5 min, and fractions corresponding to 1/
40 of a retina were resolved by SDS-PAGE in a 12% tris-glycine
gel and transferred to nitrocellulose membranes (Protran,
Schleicher & Schuell, Keene, NH). Membranes were incubated
with polyclonal antibodies to bovine GCAP2 [p24DN [1], a gift
from A. Dizhoor, Pennsylvania College of Optometry, Elkins
Park, Pennsylvania], [GC1 and GC2 [57], a gift from D. Garbers,
HHMI and UT Southwestern Medical Center, Dallas] and PDE
(abc2, Cytosignal, Irvine, CA). Immunopositive protein bands
were detected with a peroxidase-conjugated goat anti-rabbit IgG
with the ECL system (Amersham, UK).
For determination of the precise level of expression of the
transgene (expressed as a function of the endogenous), retinal
extracts from mice from bEF2GCAP2 line B and line A (2-fold
serial dilutions of retinal extracts obtained as described above)
were directly compared to retinal extracts from the bGCAP2
control line (2-fold dilutions). The expression level of bGCAP2 in
this line was previously established as 2-fold the endogenous levels
[11]. This same study established that the anti-GCAP2 antibody
used recognized bGCAP2 with a 1.5-fold higher affinity than
mGCAP2 [11]. That is the reason that we compared transgenic
bEF2GCAP2 to the transgenic bGCAP2 reference. The 2-fold
serial dilutions in each sample were used to obtain the integration
values of those bands present in the linear range in the same gel,
for a direct comparison. The expression of bEF2GCAP2 line A
was determined to be 2.7660.12 –fold the endogenous levels
(average 6 St Dev, n = 3). The expression of bEF2GCAP2 line B
was estimated to be 1.4-fold higher than line A, that is, 3.85-fold
the endogenous levels.
Histology and retinal morphometry
For histological analysis of the retina by light microscopy,
eyecups were marked for orientation, fixed, embedded in epoxy
resin and sectioned at 1 mm thickness as described previously [58].
Retinal morphometry measurements were taken as previously
described [58].
Guanylate cyclase assays
Guanylate cyclase activity was assayed in mouse retinal
homogenates. Six retinas from dark-adapted mice of each
genotype were dissected under infrared illumination, pooled and
homogenized in 112 ml of 26assay buffer (100 mM MOPS-KOH
pH 7.5, 16 mM NaCl, 200 mM KCl, 2 mM IBMX, 20 mM
MgCl2, 14 mM 2-b-mercaptoethanol). From this, 12.5 ml aliquots
were mixed with either 7.5 ml of 1.33 mM EGTA (for a final
concentration of 0.4 mM EGTA per reaction, the ‘‘low Ca2+’’
condition) or 7.5 ml of 6.6 mM CaCl2 (for a final concentration of
2 mM Ca2+, the ‘‘high Ca2+’’ condition) and preincubated at 30uC
for 10 min. Reactions were initiated by addition of 5 ml of 56
substrate mix (1.0 mM GTP, 0.2 mCi/ml of [a-32P]GTP, 1.0 mM
ATP), and allowed to proceed for 15 min at 30uC. Reactions were
terminated by addition of 500 ml of ice-cold 120 mM Zn(OAc)2,
neutralized with 500 ml of Na2CO3, kept at 280uC for 15 min
and centrifuged at 14,000 g, 4uC for 20 min. Radiolabeled cGMP
in the supernatants was separated from radiolabeled GTP by
alumina column chromatography as described [59]. Protein
concentration in retinal homogenates was determined by Brad-
ford. Results are the average and standard deviation of four
independent experiments performed in duplicate, with mice that
were between p20 and p30. Guanylate cyclase activity was also
determined in all retinal homogenates after the addition of 3 mM
recombinant GCAP2 as a control for the presence of active Ret-
GCs.
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Immunocytochemistry
To obtain retinal sections for immunofluorescence analysis
mouse eyecups were fixed, infiltrated in sucrose or acrylamide,
embedded in OCT and cryosectioned as described [34]. Sections
were incubated with blocking solution (3% normal goat serum, 1%
BSA, 0.3% Triton X100 in PBS pH 7.4, 1 h at room tempera-
ture); primary antibody (14 h at 4uC), secondary antibody (1 h at
room temperature), and fixed for 15 min in 4% paraformaldehyde
prior to being mounted with Mowiol [Calbiochem, Billerica, MA].
An antigen retrieval treatment of retinal sections [incubation in
0.05 mg/ml proteinase K in PBS pH 7.4 for 2 min at room
temperature followed by a heat shock at 70uC for 10 sec] was
needed for GCAP2 immunostaining. Antibodies used were: a
polyclonal anti-GCAP2 (35), monoclonal anti-GCAP2 [mAb2235,
Millipore, Billerica, MA], rabbit monoclonal anti-14-3-3e
[EPR3918, abcam, Cambridge, UK]. Secondary antibodies for
immunofluorescence were Alexa 488 goat anti-rabbit IgG and
Alexa 555 goat anti-mouse IgG [Molecular Probes, Eugene,
Oregon]. Images were acquired at a laser scanning confocal
microscope (Leica TCS-SL and TCS-SP2).
GCAP2 immunoprecipitation and protein identification
by LC-MS/MS
For GCAP2 immunoprecipitation in order to identify protein
interacting partners in the different phenotypes [GCAPs2/2
bGCAP2, GCAPs2/2 bEF2GCAP2 and GCAPs2/2 control
mice] forty retinas per phenotype were pooled and homogenized
in HEPES buffer [10 mM HEPES pH 8.0, 5 mM KCl, 135 mM
NaCl, 1.5 mM MgCl2, 4 mM EGTA, 1 mM PMSF, 1 mM NaF,
1 mM b-mercaptoethanol, 1% Triton-X100 and protease inhib-
itor cocktail Complete Mini (Roche, Basel, Switzerland)], and
clarified by centrifugation. Supernatants were incubated with anti-
GCAP2 monoclonal antibody-covalently crosslinked to magnetic
beads (Dynabeads, Life Technologies, Carlsbad, California) for
45 minutes at room temperature (anti-GCAP2 mAb2235, Milli-
pore, Billerica, MA). Following extensive washing, elution was
performed with 0.2M Glycine-HCl pH 2.5. Elution fractions were
neutralized and concentrated by ethanol precipitation, reduced
and alkylated with 45 mM DTT at 60uC followed by 100 mM
iodoacetamide at room temperature, dehydrated and rehydrated
with sequencing grade trypsin in 25 mM ammonium bicarbonate
for 12 h. For LC-MS/MS samples were resuspended in 0.1%
formic acid and injected into a series Proxeon LC nanoEASY
system (Thermo Fisher Scientific, West Palm Beach, Florida)
coupled to a LTQ-Velos Orbitrap (Thermo Fisher Scientific, West
Palm Beach, Florida). The resulting mass spectral peak lists were
searched with the Sequest search engine (v.2.1.04, Matrix
Sciences, London, UK) against the merged BOVIN-MOUSE
UP SP r 2011-1.fasta sequence library. Immunoprecipitation
assays and LC-MS/MS analysis with the indicated mouse
phenotypes were performed in three independent experiments,
with similar results.
In vitro phosphorylation of GCAP2 and pull-down assays
with mock- or phosphorylated-GCAP2
For in vitro phosphorylation of GCAP2 in the presence of
radioactivity, 20 ml reaction mixtures contained 8.5 mg of purified
recombinant wildtype bGCAP2 or bEF2GCAP2, purified PKGIa
(100 units, Calbiochem, Billerica, MA) and 3 mCi of 33P-cATP
(Perkin Elmer, Massachusetts, USA) in phosphorylation reaction
buffer (30 mM Tris-HCl pH 7.5, 5 mM MgCl2, 5 mM sodium
phosphate buffer pH 7.5, 6 mM DTT, 0.1 mM EGTA and
10 mM ATP). For reactions in Ca2+ or EGTA conditions, the
0.1 mM EGTA in the reaction buffer was substituted to 5 mM
CaCl2 or 2 mM EGTA, respectively. cGMP was added to
500 mM (to obtain phosphorylated GCAP2 or P-GCAP2) or not
added (mock- controls). After incubation for 2 h at 30uC and
overnight at 4uC, each reaction mixture was diluted with Laemmli
buffer and resolved by 15% SDS-PAGE. Following transfer to a
nitrocellulose membrane, an autoradiograph of the 33P phosphor-
ylation products was obtained by 15 min of exposure to a Kodak
X-ray film. The nitrocellulose membrane was subsequently
incubated with a pAb anti-GCAP2 and IRDye 800CW Goat
Anti-rabbit IgG for GCAP2 immunodetection.
To obtain phosphorylated bGCAP2 or bEF2GCAP2 for pull-
down assays in the absence of radioactivity, the same procedure
was used except that 25 mg of bGCAP2 or bEF2GCAP2 protein
and 230 units of purified PKGIa were used per reaction tube. The
product of each reaction tube was cross-linked to 2.5 mg of
magnetic beads (Life Technologies, Carlsbad, California) and used
in pull-down assays with solubilized bovine retina. Each sample
was incubated with material corresponding to 1/8 of a bovine
retina, previously homogenized in binding buffer (10 mM HEPES,
135 mM NaCl, 5 mM KCl, 1 mM PMSF, 1 mM NaF, 1 mM b-
mercaptoethanol, 1% Triton X-100, 4 mM EGTA, 2 mM
EDTA, Complete Mini protease inhibitors, pH 7.4) and pre-
cleared by centrifugation. After 1 h incubation at room temper-
ature, beads were washed and bound proteins were eluted under
acidic conditions, equilibrated and ethanol precipitated. Samples
were resolved by 15% SDS-PAGE and transferred to a
nitrocellulose membrane. For Western detection of GCAP2 and
14-3-3 the following antibodies were used: a polyclonal anti-
GCAP2 (35), a pAb to 14-3-3pan (JP18649, IBL International,
Hamburg, Germany), a mAb to 14-3-3e (EPR3918, abcam,
Cambridge, UK), a IRDye 800CW Goat anti-rabbit IgG and a
IRDye 680CW Goat anti-mouse IgG (Tebu Bio, Offenbach,
Germany). Image was acquired at the Odyssey Imaging System
(LI-COR, Lincol, Nebraska USA).
In situ phosphorylation assays
All mice for in situ phosphorylation assays were 30–36 days old.
Mice were dark-adapted for a minimum of 14 h prior to use.
Retinas were dissected under infrared light (two retinas per
phenotype per light condition) and incubated for 90 min in
600 ml of bicarbonate-buffered Locke’s solution (112.5 mM NaCl,
3.6 mM KCl, 2.4 mM MgCl2, 1.2 mM CaCl2, 10 mM HEPES,
0.02 mM EDTA, 20 mM NaHCO3, 10 mM glucose, 3 mM
sodium succinate, 0.5 mM sodium glutamate, 0.1% vitamin and
amino acids supplement) containing 1 mCi/ml [32Pi]H3PO4
(10 mCi/ml, Perkin Elmer, Massachusetts, USA) in the dark in a
5% CO2 incubator to allow incorporation of
32P in the endogenous
ATP pool. Following incubation, retinas were washed with Locke’s
solution and immediately homogenized in 200 ml of solubilization
buffer [10 mM HEPES, 135 mM NaCl, 5 mM KCl, 1 mM PMSF,
2 mM NaF, 4 mM EGTA, 1.5 mM MgCl2, 2 mM EDTA, 1%
Triton X100, complete mini protease inhibitors (Roche Applied
Sciences, Basel, Switzerland), pH 7.4] in the dark, or exposed to
bright white light for 5 min prior to homogenization. Samples were
clarified by centrifugation at 13,000 g for 20 min at 4uC and
supernatants were transferred to new tubes. From these samples,
10 ml aliquots were resolved by 15% SDS-PAGE to obtain an
autoradiograph of the input samples. Visualization of inputs
required 4 h of exposure with a Kodak X-ray film. The remaining
volume of samples (180 ml) were used to immunoprecipitate
GCAP2 with an anti-GCAP2 monoclonal antibody (anti-GCAP2
mAb2235, Millipore, Billerica, MA) coupled to magnetic beads
(Dynabeads, Life Technologies, Carlsbad, California) as described
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above. After acidic elution of bound fractions, samples were
neutralized and proteins precipitated with ethanol. Protein pellets
were resolved by 15% SDS-PAGE and transferred to a nitrocel-
lulose membrane. Visualization of phosphorylated proteins in the
bound fractions by autoradiography required 4 days of exposure
with a Kodak X-ray film. The membrane was subsequently
incubated with a polyclonal antibody anti-GCAP2 and IRDye
800CW Goat Anti-rabbit IgG; and a polyclonal antibody to 14-3-
3pan (JP18649 IBL International, Hamburg, Germany) and IRDye
680CW Goat Anti-mouse IgG, and scanned at an Odyssey Image
Acquisition system (LI-COR, Lincoln, Nebraska USA).
Analysis of steady-state GCAP2 phosphorylation by
isoelectrofocusing (IEF) gels
Retinas from mice of the indicated phenotypes were dissected
under infrared light, and each retina was solubilized in 150 ml of
buffer (10 mM Hepes pH 7.5, 1 mM MgCl2, 10 mM NaCl,
0.1 mM EDTA, 1% dodecyl-maltoside, 1 mM DTT, 50 mM
NaF) overnight at 4uC. Samples were centrifuged at 14000 rpm
for 5 min, 15 ml of the supernatant was loaded onto an
isoelectrofocusing gel (pH range 3–8) on a Pharmacia FBE 300
flat bed apparatus, and focused for 2 h at 23W. Proteins were
transferred to a nitrocellulose membrane by capillary action and
incubated with GCAP2 pAb. Bands were visualized with the ECL
system (Pharmacia).
Transient transgenic expression of bS201G/EF2GCAP2
mutant in the retina by in vivo electroporation of plasmid
DNA following its injection in the subretinal space
The expression vector for the mutant bS201G/EF2GCAP2 was
obtained by site-directed mutagenesis of the expression vector
described above for bEF2GCAP2 based on the 4.4 kb version of
the mouse opsin promoter. Site-directed mutagenesis was
performed with the QuikChange II site-directed mutagenesis kit
(Agilent, Santa Clara, CA, USA) using primers:
bGCAP2_S201G_Fw: CTCAGCAGAGGCGGAAAGGTGC-
CATGTTC; bGCAP2_S201G_Rv: GAACATGGCACCTTTC-
CGCCTCTGCTGAG;
Mutagenesis was confirmed by sequencing. Mice were electro-
porated at p0 according to reference [40] and processed at p28–
30. Briefly, 0.5 ml at a concentration of 6 mg/ml of DNA mix in
PBS was injected into the subretinal space, by making use of a
Nanojet microinjector and micromanipulator (Drummond Scien-
tific, Broomall, PA). The DNA mix consisted of the expression
vector for the specific GCAP2 mutant (bGCAP2, bEF2GCAP2 or
bS201G/EF2GCAP2) in circular form and a tracer plasmid
(pL_UG that expresses the green fluorescent protein (GFP) driven
by the Ubiquitin C promoter, [60]) also in circular form, at a mass
ratio of 2:1. Electroporation was performed with a square-wave
electroporator (CUI21, Nepagene, Japan) by triggering 5 pulses of
80 V with a 50 ms duration and an interval time of 950 ms.
Electroporated pups were raised under standard cyclic light
conditions and sacrificed at p28–30 for immunofluorescence
analysis. Briefly, eyes were fixed in 4% paraformaldehyde in
PBS at pH 7.4, embedded in acrylamide mix and frozen as
described [34]. Retinal cryosections were obtained at 22 mm
thickness. An antigen retrieval protocol was performed preceding
the immunofluorescence studies: glass slides were incubated with
proteinase K in PBS pH 7.4 (0.05 mg/ml) for 2 min and heated at
70uC for 8 sec. Sections were incubated in blocking solution (1%
BSA, 3% normal goat serum, 0.1% Triton X100, PBS pH 7.4);
primary antibody solution (1% BSA, 3% normal goat serum, PBS
pH 7.4 containing 0.01 mg/ml polyclonal antibody to GCAP2
and 0.00025 mg/ml mAb 1D4 to rhodopsin); and secondary
antibody solution (1% BSA, 3% normal goat serum, PBS pH 7.4
containing Alexa Fluor 647 anti-rabbit IgG (signal converted to
red in figures); and Alexa Fluor 555 anti-mouse IgG (signal
converted to blue in figures). Images were acquired in a Leica
confocal microscope. GCAP2 and rhodopsin signal profiles were
obtained for the individual cells shown by tracing a line along the
inner segment compartment, and another line along the outer
segment compartment, and plotting the summation of the red and
the green signal along both lines from the collection of planes in a
z-stack that covers the whole volume of the cell, by using the Leica
confocal software (Leica Microsystems).
Analysis of the effect of 30 days of constant light
exposure versus 30 days of dark rearing on GCAP2
subcellular distribution in wildtype mice
Three-month old C57Bl/6J mice were kept in a ventilated dark
cabinet for 30 d, or kept under constant light exposure for the
same time (fluorescent light, 700 lux intensity inside the cage), and
their eyecups were processed for immunofluorescence analysis.
Retinal cryosections were stained with an anti-GCAP2 pAb and
anti-rhodopsin mAb 1D4, by indirect immunofluorescence stain-
ing with Alexa 488 goat anti-rabbit IgG and Alexa 555 goat anti-
mouse IgG (Molecular Probes, Eugene, Oregon). Z-axis stacks
were obtained from four mice per condition at a Leica TCS-SL
confocal microscope, and the percentage of GCAP2 signal
colocalizing with the rhodopsin signal at the rod outer segment
was quantified by ImageJ in three representative planes from each
stack, one stack per mouse, four mice per condition. Precisely, for
a 636-objective frame of retina, an ROI was defined to include
the inner and outer segment layers, while another ROI was
delimited to the outer segment layer based on rhodopsin staining.
GCAP2 signal was quantified in each ROI, and the percentage of
GCAP2 colocalizing with rhodopsin was expressed as a function of
GCAP2 at the inner and outer segment layers (ImageJ). Mean
values were obtained and statistical analysis performed with
GraphPad Prism 6.
Electroretinogram
Electroretinogram responses to flash stimuli were recorded on a
Nicolet Electrovisual Diagnostic System. Mice were dark-adapted
for 12 h and then anesthetized under dim red light by
intraperitoneal administration of Ketamine HCl (100 mg/kg)
and Xylazine HCl (10 mg/kg). Phenylephrine HCl (2.5%) and
Tropicamide (0.5%) were applied to the cornea to dilate the
pupils, and mice were dark-adapted again for 10 min previous to
the recording. Following administration of Tetracaine HCl (0.5%)
eyedrops as a topical corneal anesthetic, the mice are placed on a
heated pad at 37uC in a Faraday cage. The corneal electrode
consisted of a carbon-fiber moistened in saline. A 1 ms light flash
was delivered through a fiber optic centered vertically over a few
millimeter of the corneal surface. Mice from the different
genotypes were recorded over the course of eight months under
identical conditions.
Effect of constant light-rearing versus constant dark-
rearing on retinal morphology of GCAPs2/2
bEF2GCAP2 and GCAPs2/2 bGCAP2 control mice
Evaluation of the rate of retinal degeneration by retinal
morphometry analysis. The indicated mice were either
reared in constant darkness or under constant light exposure
(fluorescent light, 1500 lux intensity) and processed for analysis at
postnatal day 20 or 40. Eyecups were marked for orientation,
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embedded in epoxy resin and section at 1 mm thickness as
described previously [34].
Measurements of ONL thickness were taken by making use of a
camera lucida attached to a microscope, with the aid of a graphics
tablet (WACOM, Vancouver, WA) and the Axiovision LE Rel.4.1.
imaging software (Carl Zeiss Inc., Germany). A stage micrometer
(Klarmann Rulings, Litchfield, NH) was used for calibration. Each
retina half (superior and inferior) was divided into ten equal
segments from the optic nerve to the tip (excluding a radius of
100 mm from the optic nerve, due to the natural thinning of the
ONL at this region). Three independent measurements were taken
per segment, and the average value was obtained. In this manner
60 independent measurements were obtained per section (20
segments63 measurements/segment). The mice analyzed per
genotype were: GCAPs2/2 bEF2GCAP2 line A, n = 4 for each
dark and light conditions; GCAPs2/2 bGCAP2 line E, n = 3 for
each dark and light conditions; and GCAPs 2/2 control line,
n = 2 for each condition.
Supporting Information
Figure S1 Determination of bEF2GCAP2 transgenic expression
levels in lines A and B. A. The level of expression of bEF2GCAP2
in line A was determined by direct comparison with that of
bGCAP2 in line E, by loading in the same gel two-fold serial
dilutions of a retinal homogenate representing 1/40 of a retina.
Expression of bEF2GCAP2 was determined to be 1.38-fold higher
(60.06 St Dev) than that of bGCAP2 in control line E. Because
line E was previously established to express 2-fold the endogenous
levels of GCAP2 [11], line A is determined to express 2,76-fold the
endogenous levels of GCAP2. B. Likewise, by comparison to line
A, line B was determined to express 1.4-fold more transgene, or
3.86-fold the endogenous GCAP2 levels.
(TIF)
Figure S2 Timecourse for the loss of visual function in
bEF2GCAP2 expressing mice as assessed by electroretinogram.
ERG B-wave amplitudes (mV) are plotted to postnatal age of mice
(months). Representative ERG responses are shown for each
phenotype at 4 and 7.5 months of age.
(TIF)
Figure S3 Light-rearing does not prevent or delay retinal
degeneration in bEF2GCAP2 transgenic mice. Rationale. If
bEF2GCAP2 expression led to unabated cGMP synthesis in vivo
and accumulation of cGMP was the basis of the pathology, then
conditions of constant light exposure would slow the retinal
degeneration by causing the sustained activation of PDE6 activity
and cGMP hydrolysis. Light induced sustained cGMP hydrolysis
would counteract unabated cGMP synthesis. A. Statistical compar-
ison of ONL thickness at fixed regions along the central retina
between bEF2GCAP2 transgenic mice reared in complete darkness
or under constant light exposure (1,500 lux fluorescent light) at
postnatal day 40. Measurements of ONL thickness (mm) were taken
at ten equal intervals along the superior and inferior hemispheres of
the retina, indicated in abscissas as positive values (superior retina)
and negative values (inferior retina) from the optic nerve (position 0).
The superimposition of the red and black lines indicate that retinal
degeneration (shortening of ONL thickness along the retina) was
observed to the same extent in dark-reared or constant light-reared
bEF2GCAP2 mice. ONL thickness in GCAPs2/2 bGCAP2 line
E control mice are shown as a reference of normal retina values. B.
Representative pictures from central superior retinas of dark-reared
and constant light-reared GCAPs2/2 bEF2GCAP2 line A and
control mice at 20 and 40 postnatal days.
(TIF)
Figure S4 Additional images and GCAP2 staining profiles of
cells from electroporated mice. Photoreceptor cells from electro-
porated mice with bGCAP2 (A, 1 cell), bEF2GCAP2 (B, 6 cells),
and bS201G/EF2GCAP2 (C, 9 cells). GCAP2 stained in green,
rhodopsin in red.
(TIF)
Table S1 Spectral counting of Proteins identified by LC-MS/
MS in GCAP2 immunoprecipitation experiments.
(XLSX)
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